A PYMNTS Company

US: Teva Pharmaceuticals to increase offer for Mylan to $43 billion

By  |  July 6, 2015

Teva Pharmaceuticals Industries is planning to increase its offer to acquire Mylan to as much as $43 billion, according to report from Bloomberg based on information from people familiar with the situation.

The people suggested that Teva Pharmaceuticals would announce its sweetened offer as early as this week. It is likely for Teva Pharmaceuticals to raise its acquisition proposal for Mylan between $86 and $88 per share.

According to the people, Teva Pharmaceuticals intend to formally submit its proposal to Mylan as part of its strategy to prevent it from pursuing its acquisition of Perrigo Company.

Full content: Bloomberg

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.